CUTRUPI, SEBASTIANO
 Distribuzione geografica
Continente #
AS - Asia 1.489
NA - Nord America 1.018
EU - Europa 377
SA - Sud America 371
Continente sconosciuto - Info sul continente non disponibili 50
AF - Africa 35
OC - Oceania 5
Totale 3.345
Nazione #
US - Stati Uniti d'America 949
SG - Singapore 689
BR - Brasile 285
CN - Cina 281
HK - Hong Kong 178
IT - Italia 146
VN - Vietnam 126
FR - Francia 105
BD - Bangladesh 73
KR - Corea 36
CA - Canada 34
GB - Regno Unito 26
DE - Germania 24
IN - India 22
AR - Argentina 21
NL - Olanda 19
EC - Ecuador 17
JP - Giappone 16
CO - Colombia 15
ID - Indonesia 14
VE - Venezuela 12
FI - Finlandia 10
MX - Messico 10
ZA - Sudafrica 9
MA - Marocco 7
PE - Perù 7
PH - Filippine 7
PL - Polonia 6
TR - Turchia 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
IE - Irlanda 5
RU - Federazione Russa 5
SA - Arabia Saudita 5
CR - Costa Rica 4
IL - Israele 4
IQ - Iraq 4
KE - Kenya 4
MY - Malesia 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
ES - Italia 3
HN - Honduras 3
HR - Croazia 3
JM - Giamaica 3
LT - Lituania 3
NP - Nepal 3
PK - Pakistan 3
SE - Svezia 3
TH - Thailandia 3
AO - Angola 2
AU - Australia 2
BE - Belgio 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
GT - Guatemala 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
PY - Paraguay 2
TN - Tunisia 2
AL - Albania 1
AT - Austria 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MR - Mauritania 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PW - Palau 1
RO - Romania 1
RS - Serbia 1
RW - Ruanda 1
TW - Taiwan 1
Totale 3.296
Città #
Singapore 434
Santa Clara 251
Hong Kong 177
San Jose 95
Hefei 91
Lauterbourg 88
Ashburn 73
Beijing 54
Ho Chi Minh City 44
Seoul 36
Los Angeles 30
Hanoi 27
New York 23
São Paulo 21
Dallas 18
Milan 17
Buffalo 12
Frankfurt am Main 11
Toronto 11
Tokyo 10
Rio de Janeiro 9
Rome 9
Chicago 8
Council Bluffs 8
Da Nang 8
Belo Horizonte 7
Guayaquil 7
Washington 7
Atlanta 6
Brasília 6
Brooklyn 6
Catania 6
Helsinki 6
Quito 6
Bauru 5
Biên Hòa 5
Dhaka 5
Düsseldorf 5
Jakarta 5
Louisville 5
New Orleans 5
Phoenix 5
Tampa 5
The Bronx 5
Warsaw 5
Baghdad 4
Belém 4
Bologna 4
Curitiba 4
Dublin 4
Florence 4
Haiphong 4
Hải Dương 4
Medellín 4
Miami 4
Montevideo 4
Montreal 4
Queens 4
San José 4
Santo André 4
Amsterdam 3
Boston 3
Cali 3
Cape Town 3
Chennai 3
Cleveland 3
Fort Lauderdale 3
Georgetown 3
Greensboro 3
Houston 3
Johannesburg 3
Juiz de Fora 3
Kansas City 3
Kathmandu 3
Lappeenranta 3
Lima 3
Magé 3
Maracaibo 3
Minamishinagawa 3
Mumbai 3
Naples 3
Ninh Bình 3
Paternò 3
Providence 3
Richmond 3
Sacramento 3
Salvador 3
San Antonio 3
Vitória da Conquista 3
Zagreb 3
Aci Catena 2
Addis Ababa 2
Ajax 2
Ananindeua 2
Athens 2
Auckland 2
Augusta 2
Bari 2
Bedford 2
Bengaluru 2
Totale 1.847
Nome #
Role of Gut Microbiota in Overweight Susceptibility in an Adult Population in Italy 134
Osteopontin, death and cardiovascular events in stage G3–4 CKD patients: a joint model analysis 92
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass 78
Raised Asymmetric Dimethyl Arginine (ADMA) is associated with high Plasma Norepinephrine (NE) in patients with End Stage Renal Disease (ESRD). 70
Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients 70
Reducing salt intake by urine chloride self-measurement in non-compliant patients with chronic kidney disease followed in nephrology clinics: a randomized trial 68
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass 67
Adiponectin, the most abundant adipocyte-derived protein, is functionally related to metabolic risk factors and predicts cardiovascular events in patients with end stage renal disease 64
Diagnostic value of troponin-t for alterations in left ventricular mass and function in dialysis patients 60
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study 58
FGF23 and the PTH response to paricalcitol in chronic kidney disease 56
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity 55
Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). 53
Intact FGF23 and ?-klotho during acute inflammation/sepsis in CKD patients 52
Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. 51
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 50
Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial 47
Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients. 47
Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients 47
Resistin and all-cause and cardiovascular mortality: Effect modification by adiponectin in end-stage kidney disease patients 47
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 45
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients 45
Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortatlity in hemodialysis patients. 43
L'obesità addominale interagisce con due citochine prodotte dal tessuto adiposo, Leptina ed Adiponectina, per predire il rischio di mortalità totale e cardiovascolare nei pazienti in dialisi. 42
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD) 42
Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. 41
I polimorfismi del gene ENPP1 si associano ad ipertrofia ventricolare sinistra ed alla funzione sistolica nei pazienti in dialisi. 41
INDICES OF INSULIN RESISTANCE AND RISK OF TOTAL AND CARDIOVASCULAR MORTALITY IN DIALYSIS PATIENTS 39
C-Reactive Protein and Interleukin-6 modify the risk of high levels of Asymmetric Dimethyl-Arginine (ADMA) for death and cardiovascular events in end stage renal diseases patients. 37
Prospective study of Neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. 36
Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD). 36
Il rischio di progressione delle nefropatie croniche e mortalità: ruolo dell'Asymmetrical Di-Methil-Arginine (ADMA). 34
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in ckd patients. 33
Low triiodothyronine and survival in end stage renal disease (ESRD). 33
Urotensin II and cardiomyopathy in end-stage renal disease. 32
FGF23 beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease patients. 32
L'attività simpatica è strettamente correlata ai livelli corcolanti di dimetil arginina asimmetrica (ADMA) nei pazienti in trattamento emodialitico 32
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 32
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease 32
Plasma nor-epinephrine predicts survival and incident cardiovascular events in patients with end stage renal disease 31
Sympathetic activity and asymmetric dimethyl arginine (ADMA) in patients with end stage renal disease (ESRD). 30
Pattern evolutivo dei biomarcatori di infiammazione e dei fattori di rischio non tradizionali dopo trapianto renale. 30
Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD 30
Low triiodothyronine and survival in end-stage renal disease. 30
Urotensin II is inversely related to markers of endothelial activation and inflammation and is an inverse predictor of incident cardiovascolar events in end stage renal disease (ESRD). 29
Norepinephrine and concentric hypertrophy in patients with end stage renal disease. 29
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end stage renal disease (ESRD). 29
L'infiammazione amplifica il rischio di mortalità ed eventi cardiovascolari connesso ai livelli circolanti di dimetilarginina asimmetrica (ADMA) nei pazienti in dialisi. 29
Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease 28
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 28
Vascular endothelial growth factor (VRGF) is a marker of left ventricular dysfunction and predicts mortality in hemodialysis (HD) patients. 28
Vitamin D levels and patient outcome in chronic kidney disease. 27
L'iperparatiroidismo e il TNF-a come determinanti dell'incidenza di fratture nei pazienti in dialisi: uno studio di coorte. 27
Salt intake and inflammation in essential hypertension. 27
Vascular Endothelial Growth Factor, rimodellamento ventricolare sinistro e disfunzione sistolica nei pazienti in dialisi 27
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 27
La riduzione dell'intake di sale influenza l'infiammazione nell'ipertensione arteriosa essenziale? 27
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 27
Waist circumference modifies the relationship of adipose tissue cytochines leptin and adiponectin with all-cause and cardiovascular mortality in end stage renal disease (ESRD). 27
Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcome stage renal disease patients. 26
Low Triiodothyronine and Cardiomyopathy in Patients with End-Stage Renal Disease (ESRD). 26
Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. 26
Salivary and lacrimal secretion is reduced in patients with ESRD. 26
Urotensin II partecipates in cardiovascular control in end stage renal disease (ESRD). 25
Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides 25
La riduzione dell'intake di sale influenza l'infiammazione nell'ipertensione arteriosa essenziale? 25
Beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease (CKD) patients. 25
Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease 24
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. 24
Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study 24
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 24
Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. 24
La riduzione dell intake di sale influenza l infiammazione nell ipertensione arteriosa essenziale? 24
La riduzione dell'intake di sale influenza l'infiammazione nell'ipertensione arteriosa essenziale? 23
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in CKD patients. 23
I predittori degli eventi cardiovascolari nei pazienti in dialisi. 23
L'ipotiroidismo subclinico si associa alla micro-infiammazione cronica e predice la mortalità nei pazienti in CAPD. Risultati di uno studio pilota di coorte. 23
La concentrazione plasmatica di Neuropeptide Y è correlata ai livelli circolanti di Noradrenalina e predice l'incidenza di eventi cardiovascolari (CV) nei pazienti in dialisi. 22
Smoking and hyperparathyroidism in patients with end stage renal disease (ESRD). 22
Valore diagnostico per il basso turnover osseo del PTH dosato con metodi RIA di prima e seconda generazione. 22
Neuropeptide Y (NPY), norepinephrine and incident cardiovascular events in and-tage renal disease (ESRD). 21
Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. 21
Vascular endothelial growth factor, left ventricular remodeling and systolic dysfunction in end stage renal disease 21
Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections 21
Which is the best inflammation marker? A comparative study based on multivariate modelling of mortality in end stage renal disease (ESRD) patients. 20
Thyroid sick syndrome e miocardiopatia nei pazienti con insufficienza renale cronica. 19
Diagnostic value for low bone turnover of first and second generation immuno-radiometric PTH assay. 19
Low Triiodothyronine (fT3): a new facet of inflammation in end stage renale disease (ESRD). 19
Urotensina II e fattori di rischio cardiovascolare nei pazienti con insufficienza renale cronica in trattamento dialitico. 19
Livelli circolanti di tiiodrotironina (fT3) e mortalità nei pazienti in dialisi. 19
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease 18
Does sub-clinical hypothyroidism predict survival in patients on Continuous Ambulatory Peritoneal Dialysis? 18
Il fumo amplifica il rischio di iperparatiroidismo secondario nei pazienti in dialisi. 17
Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis 17
Vascular Endothelial Growth Factor, Inflammation, Cardiomyopathy and Mortality in End-Stage-Renal Disease (ESRD) 16
Asymmetrical Di-Methyl-Arginine (ADMA) predicts progression to dialysis and death in patients with chronic kidney disease (CKD). 14
Totale 3.345
Categoria #
all - tutte 12.309
article - articoli 6.741
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.050


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202427 0 0 0 0 0 0 0 0 24 0 3 0
2024/20251.143 5 9 94 77 258 11 13 53 24 39 290 270
2025/20261.778 70 162 175 249 321 54 275 135 77 102 123 35
2026/2027397 119 74 204 0 0 0 0 0 0 0 0 0
Totale 3.345